May. 31 at 3:21 PM
$IMNM $SMMT Watching biotech flow heat up after fresh oncology updates hitting the tape.
$IMNM reports Ringside trial cleared both primary and secondary endpoints, that’s a clean clinical de-risking event and the kind of headline algos don’t ignore in early price discovery.
On the other side,
$SMMT dropping ASCO data from AK112-206 in first-line mCRC, ivonescimab combo showing 70.8% ORR with mFOLFOX6, stacked against historical bevacizumab-based regimens. That’s a strong signal in a space where incremental efficacy matters.
Feels like market is quietly repricing oncology innovation again. Question is simple, does momentum follow data quality this time or fade into conference noise?
